A5038639715- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Meningioma and schwannoma management
- Pancreatic and Hepatic Oncology Research
- ATP Synthase and ATPases Research
- Vascular Malformations Diagnosis and Treatment
- Pituitary Gland Disorders and Treatments
- Vestibular and auditory disorders
- Multiple Sclerosis Research Studies
- IgG4-Related and Inflammatory Diseases
- Neurofibromatosis and Schwannoma Cases
- Cancer, Hypoxia, and Metabolism
- Vasculitis and related conditions
- Ear Surgery and Otitis Media
- Intracerebral and Subarachnoid Hemorrhage Research
- Head and Neck Anomalies
- Protein Degradation and Inhibitors
- Systemic Lupus Erythematosus Research
- Hearing, Cochlea, Tinnitus, Genetics
- Sarcoidosis and Beryllium Toxicity Research
- Colorectal Cancer Treatments and Studies
- MicroRNA in disease regulation
- Machine Learning in Materials Science
- Oral and Maxillofacial Pathology
- Amyloidosis: Diagnosis, Treatment, Outcomes
Amsterdam University Medical Centers
2012-2024
Vrije Universiteit Amsterdam
2012-2024
Assistance Publique – Hôpitaux de Paris
2022
Roche (Switzerland)
2022
Inserm
2022
Université Paris-Saclay
2022
Université Paris-Sud
2022
Centre Hospitalier Sainte-Anne
2022
Amsterdam UMC Location Vrije Universiteit Amsterdam
2011-2020
Although diffuse intrinsic pontine glioma (DIPG) carries the worst prognosis of all pediatric brain tumors, studies on prognostic factors in DIPG are sparse. To control for confounding variables studies, which generally include relatively small patient numbers, a survival prediction tool is needed. A multicenter retrospective cohort study was performed Netherlands, UK, and Germany with central review clinical data MRI scans children DIPG. Cox proportional hazards backward regression used to...
Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40 years of mostly single-center, often non-randomized trials with variable patient inclusions, there has been no improvement in survival. It therefore time for international collaboration DIPG research, to provide new hope children, parents medical professionals fighting DIPG. In first step towards collaboration, 2011, network biologists clinicians working the field was established within European...
Background Diffuse midline gliomas (DMG) are characterized by a high incidence of H3 K27 mutations and poorer outcome. The HERBY trial has provided one the largest cohorts pediatric DMGs with available radiologic, histologic-genotypic, survival data. Purpose To define MRI molecular characteristics DMG. Materials Methods This study is secondary analysis prospective (HERBY; ClinicalTrials.gov identifier, NCT01390948) undertaken between October 2011 February 2016. Among 121 participants, 50 had...
Standards for residual tumour measurement after resection of gliomas with no or minimal enhancement have not yet been established. In this study volumes on early and late postoperative T2-/FLAIR-weighted MRI are compared.A retrospective cohort included 58 consecutive glioma patients preoperative gadolinium enhancement. Inclusion criteria were first-time between 2007 2009 a T2-/FLAIR-based target volume availability preoperative, (<48 h) (1-7 months) MRI. The non-enhancing T2/FLAIR tissue...
The availability of various first-line treatment modalities for acromegaly and evolving surgical techniques emphasize the need accurately defined predictors outcome. We retrospectively analysed outcome 30 patients with after initial endoscopic transsphenoidal surgery in two university hospitals from 2001 until 2009, reviewed comparable literature investigating predictive tumor characteristics. Medical records were monitored patient Each pituitary magnetic resonance imaging (MRI) scan was...
Abstract Introduction This study investigates the safety, tolerability, and preliminary efficacy of combined treatment with VEGF inhibitor bevacizumab, topoisomerase I irinotecan, EGFR erlotinib in children progressive diffuse intrinsic pontine glioma (DIPG). Methods Biweekly bevacizumab (10 mg/kg) irinotecan (125 mg/m 2 ) were daily erlotinib. Two cohorts received increasing doses (65 85 following a 3 + dose-escalation schedule, until disease progression maximum one year. Dose-limiting...
Abstract Previously, the tyrosine kinase inhibitor sunitinib failed to show clinical benefit in patients with recurrent glioblastoma. Low intratumoural accumulation glioblastoma was reported as a possible explanation for lack of therapeutic benefit. We designed randomized phase II/III trial evaluate whether high-dose intermittent schedule, aimed increase drug concentrations, would result improved compared standard treatment lomustine. Patients were 1:1 300 mg once weekly (Q1W, part 1) or 700...
Determination of tumor response to treatment in neuro-oncology is challenging, particularly when antiangiogenic agents are considered. Nontumoral factors (eg, blood-brain barrier disruption, edema, and necrosis) can alter contrast enhancement independent true response/progression. Furthermore, gliomas often infiltrative, with nonenhancing components. In adults, the Response Assessment Neuro-Oncology (RANO) criteria attempted address these issues. No such guidelines exist yet for children....
Studies on the associations between preoperative cerebral edema, cognitive functioning, and health-related quality of life (HRQOL) in WHO grade I meningioma patients are virtually lacking. We studied association edema postoperative functioning HRQOL 6 months postoperatively patients.Twenty-one consecutive patients, who underwent surgery, were matched individually for age, gender, educational level to healthy controls. Tumor volume assessed T1- T2-weighted MRI images, respectively. At least 5...
The HERBY trial evaluated the benefit of addition antiangiogenic agent Bevacizumab (BEV) to radiotherapy/temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma (HGG). work presented here aims correlate imaging characteristics and outcome measures pathologic molecular data.
Surgery followed by chemoradiation and adjuvant chemotherapy is standard of care for patients with a glioblastoma (GBM). Due to its limited benefit, an upfront method predict dismal outcome would prevent unnecessary toxic treatment. We searched predictive blood derived biomarker in cohort 55 GBM. Increasing age (HR 1.03, 95 % CI 1.01-1.06), postoperative tumor residue 1.07, 1.02-1.15) were independently associated unfavourable progression free survival (PFS) these patients. Corticosteroid...
ABSTRACT INTRODUCTION Immunotherapeutic agents against amyloid beta (Aβ) are associated with adverse events, including amyloid‐related imaging abnormalities edema and effusion (ARIA‐E). Recently, a magnetic resonance (MRI) rating scale was developed for ARIA‐E detection classification. The aim of this study to validate the use in larger patient group multiple raters. METHODS MRI scans 75 patients (29 known 46 control subjects) were analyzed by five neuroradiologists different degrees...
The clinico-radiological paradox in multiple sclerosis (MS) is well recognized, relevant and yet poorly understood. suitability of an vivo model for the was tested, using internuclear ophthalmoplegia (INO) medial longitudinal fasciculus (MLF).In this cross-sectional study lesions MLF were rated by experienced MS neuroradiologist blinded to all other information. presence INO objectively determined a validated infrared oculography protocol (DEMoNS). Clinical information, including National...
<h3>BACKGROUND AND PURPOSE:</h3> HERBY was a Phase II multicenter trial setup to establish the efficacy and safety of adding bevacizumab radiation therapy temozolomide in pediatric patients with newly diagnosed non–brain stem high-grade gliomas. This study evaluates implementation radiologic aspects HERBY. <h3>MATERIALS METHODS:</h3> We analyzed multimodal imaging compliance rates scan quality for participating sites, adjudication reading times central review process, influence different...
Regional collaboration and appropriate referral management are crucial in neuro-oncological care. Lack of electronic access to medical records across health care organizations impedes interhospital consultation may lead incomplete delayed referrals. To improve management, we have established a multidisciplinary triage panel (NOTP) with digital image exchange determined the effects on times, costs, time investment. A prospective cohort study was conducted from February 2019 March 2020. All...
BACKGROUND: Pediatric Diffuse intrinsic pediatric glioma (DIPG) remained dismal regardless of the new therapeutic and technical attempts.PURPOSE: To investigate efficacy toxicity hypofractionated radiotherapy in DIPG compared to conventional determine prognostic factors for its overall (OS) progressionfree survival (PFS).PATIENTS AND METHODS: Sixty four children, below age 18 years, who presented Children's Cancer Hospital, Egypt (CCHE) during period July 2007 2011 were randomized into 2...
Abstract Background: Glioblastoma, the most common primary brain tumor in adults, universally recurs with dismal prognosis. Treatment of recurrent disease second-line chemotherapy has limited impact on progression-free and overall survival. To date, clinical trials newly developed protein kinase inhibitors (PKIs) failed to demonstrate efficacy glioblastoma despite fact that essential signaling pathways responsible for growth are targeted by these agents. One main reasons hypothesized this...